Trever G. Bivona, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Trever G. Bivona, MD, PhD

Assistant Professor, Hematology and Oncology, UCSF

TBivona@medicine.ucsf.edu

Phone: (415) 885-3882 [Clinic]; (415) 353-9927 [Asst]; (415) 476-9907 [lab]
600 16th Street
San Francisco, CA 94158

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics» Cancer Genetics

Additional Websites


Education

Vanderbilt University, B.S., 1998, Molecular Biology
New York University, School of Medicine, Ph.D., 2004, Cell and Mol. Biology
New York University, School of Medicine, M.D., 2005, Medicine
Brigham and Women’s Hospital/Harvard, 2005-2007, Internal Medicine
Memorial Sloan-Kettering Cancer Center, 2007-2011, Medical Oncology


Professional Experience

  • 1998-2005
    MD-PhD, Medical Scientist Training Program, NYU School of Medicine
  • 2005-2007
    Resident House Staff, Internal Medicine, Brigham and Women’s Hospital
  • 2007-2011
    Medical Oncology Fellow, Memorial Sloan-Kettering Cancer Center
  • 2008-2011
    Research Fellow, Laboratory of Charles Sawyers, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
  • 7/2011-present
    Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco
  • 7/2011- present
    Member, UCSF Helen Diller Comprehensive Cancer Center
  • 7/2011- present
    Faculty Member, California Institute for Quantitative Biosciences (QB3)

Honors & Awards


  • 1998
    Vanderbilt University Honors Degree in Molecular Biology
  • 1998
    Vanderbilt University Research Excellence Award
  • 1998-2005
    NIH Medical Scientist Training Program Award
  • 2005
    Medical Science Writing Award, NYU School of Medicine
  • 2007
    US Patent 20060083742 Prenyl-electrostatic Switch
  • 2008-2010
    Charles A. Dana Foundation Clinical Scholars Research Fellowship
  • 2009
    Julia Zelmanovich Young Alumnus Award, NYU School of Medicine
  • 2010
    American Society of Clinical Oncology Young Investigator Award
  • 2010
    Uniting Against Lung Cancer Research Investigator
  • 2011
    NIH/NCI Clinical Investigator Career Development Award (K08)
  • 2012
    National Lung Cancer Partnership Young Investigator Award
  • 2012
    Sidney Kimmel Foundation Kimmel Scholar Award
  • 2012
    Damon Runyon Clinical Investigator Award Finalist
  • 2012
    Doris Duke Clinical Scientist Development Award
  • 2012
    American Lung Association Lung Cancer Discovery Award
  • 2012
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2012
    Visiting Scholar Howard Hughes Medical Institute (HHMI) Scholars Program at California, State University-Fullerton
  • 2012
    NIH Director's New Innovator Award (DP2)


Selected Publications

  1. Zill OA, Greene C, Sebisanovic D, Siew L, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson E. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Jun 24.
    View on PubMed
  2. Flaherty KT, Wargo JA, Bivona TG. YAP in MAPK pathway targeted therapy resistance. Cell Cycle. 2015 Jun 18; 14(12):1765-6.
    View on PubMed
  3. Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona TG. Oncogenic activation of the PI3-kinase p110ß isoform via the tumor-derived PIK3Cß(D1067V) kinase domain mutation. Oncogene. 2015 May 18.
    View on PubMed
  4. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. AXL Mediates Resistance to PI3Ka Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell. 2015 Apr 13; 27(4):533-46.
    View on PubMed
  5. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. NF-?B-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Cell Rep. 2015 Mar 31.
    View on PubMed
  6. Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM. AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells. PLoS One. 2015; 10(3):e0119832.
    View on PubMed
  7. Pazarentzos E, Bivona TG. Adaptive stress signaling in targeted cancer therapy resistance. Oncogene. 2015 Feb 23.
    View on PubMed
  8. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
    View on PubMed
  9. Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X, Yu L, Zou Z, Xie L, Costa C, Bivona T, Rosell R, Liu B. Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. J Transl Med. 2014; 12(1):355.
    View on PubMed
  10. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014 Sep; 40(8):990-1004.
    View on PubMed
  11. Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014 Apr 1; 20(7):2001-10.
    View on PubMed
  12. Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):E748-57.
    View on PubMed
  13. Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat. 2014 Mar; 35(3):318-28.
    View on PubMed
  14. Okimoto RA, Bivona TG. Recent advances in personalized lung cancer medicine. Per Med. 2014; 11(3):309-321.
    View on PubMed
  15. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013 Aug 24; 382(9893):720-31.
    View on PubMed
  16. Sabnis AJ, Bivona TG. FGFR fusions in the driver's seat. Cancer Discov. 2013 Jun; 3(6):607-9.
    View on PubMed
  17. Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 2013 Apr; 14(4):304-14.
    View on PubMed
  18. Neel DS, Bivona TG. Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clin Cancer Res. 2013 Jan 1; 19(1):3-5.
    View on PubMed
  19. Blakely CM, Bivona TG. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2012 Oct; 2(10):872-5.
    View on PubMed
  20. Lin L, Bivona TG. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract. 2012; 2012:817297.
    View on PubMed

Go to UCSF Profiles, powered by CTSI